These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36343410)

  • 41. GPR40 partial agonist MK-2305 lower fasting glucose in the Goto Kakizaki rat via suppression of endogenous glucose production.
    Miller C; Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Bunzel M; Cao J; Souza S; Thomas-Fowlkes B; Di Salvo J; Weinglass AB; Li X; Myers RW; Knagge K; Carrington PE; Hagmann WK; Trujillo ME
    PLoS One; 2017; 12(5):e0176182. PubMed ID: 28542610
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes.
    Christiansen E; Hansen SV; Urban C; Hudson BD; Wargent ET; Grundmann M; Jenkins L; Zaibi M; Stocker CJ; Ullrich S; Kostenis E; Kassack MU; Milligan G; Cawthorne MA; Ulven T
    ACS Med Chem Lett; 2013 May; 4(5):441-445. PubMed ID: 23687558
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery of novel selective GPR120 agonists with potent anti-diabetic activity by hybrid design.
    Sheng R; Yang L; Zhang Y; Xing E; Shi R; Wen X; Wang H; Sun H
    Bioorg Med Chem Lett; 2018 Aug; 28(15):2599-2604. PubMed ID: 29980358
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
    Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
    J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Yhhu4488, a novel GPR40 agonist, promotes GLP-1 secretion and exerts anti-diabetic effect in rodent models.
    Guo DY; Li DW; Ning MM; Dang XY; Zhang LN; Zeng LM; Hu YH; Leng Y
    Biochem Biophys Res Commun; 2015 Oct; 466(4):740-7. PubMed ID: 26417688
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery and development of CPL207280 as new GPR40/FFA1 agonist.
    Mach M; Bazydło-Guzenda K; Buda P; Matłoka M; Dzida R; Stelmach F; Gałązka K; Wąsińska-Kałwa M; Smuga D; Hołowińska D; Dawid U; Gurba-Bryśkiewicz L; Wiśniewski K; Dubiel K; Pieczykolan J; Wieczorek M
    Eur J Med Chem; 2021 Dec; 226():113810. PubMed ID: 34537444
    [TBL] [Abstract][Full Text] [Related]  

  • 47. GPR120 agonists for the treatment of diabetes: a patent review (2014 present).
    Zhang X; Macielag MJ
    Expert Opin Ther Pat; 2020 Oct; 30(10):729-742. PubMed ID: 32799609
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Polar aromatic periphery increases agonist potency of spirocyclic free fatty acid receptor (GPR40) agonists inspired by LY2881835.
    Krasavin M; Lukin A; Bagnyukova D; Zhurilo N; Golovanov A; Zozulya S; Zahanich I; Moore D; Tikhonova IG
    Eur J Med Chem; 2017 Feb; 127():357-368. PubMed ID: 28076825
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Role and Future of FFA1 as a Therapeutic Target.
    Ghislain J; Poitout V
    Handb Exp Pharmacol; 2017; 236():159-180. PubMed ID: 27807697
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery and biological evaluation of novel G protein-coupled receptor 119 agonists for type 2 diabetes.
    Zhou Y; Wang Y; Zhang L; Tang C; Feng B
    Arch Pharm (Weinheim); 2019 Apr; 352(4):e1800267. PubMed ID: 30740769
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability.
    Christiansen E; Due-Hansen ME; Urban C; Grundmann M; Schmidt J; Hansen SV; Hudson BD; Zaibi M; Markussen SB; Hagesaether E; Milligan G; Cawthorne MA; Kostenis E; Kassack MU; Ulven T
    J Med Chem; 2013 Feb; 56(3):982-92. PubMed ID: 23294321
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.
    Negoro N; Sasaki S; Mikami S; Ito M; Tsujihata Y; Ito R; Suzuki M; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Morohashi A; Nonaka M; Matsunaga S; Yasuma T; Momose Y
    J Med Chem; 2012 Apr; 55(8):3960-74. PubMed ID: 22490067
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structure-based design of free fatty acid receptor 1 agonists bearing non-biphenyl scaffold.
    Li Z; Chen Y; Zhang Y; Jiang H; Liu Y; Chen Y; Zhang L; Qian H
    Bioorg Chem; 2018 Oct; 80():296-302. PubMed ID: 29980115
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel GPR40 agonists.
    Jiang XW; Jiang BE; Liu H; Liu ZT; Hu LL; Liu M; Lu W; Zhang HK
    Eur J Med Chem; 2018 Oct; 158():123-133. PubMed ID: 30212763
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Free fatty acid receptor 1: a ray of hope in the therapy of type 2 diabetes mellitus.
    Arora A; Behl T; Sehgal A; Singh S; Sharma N; Chigurupati S; Kaur R; Bhatia S; Al-Harrasi A; Vargas-De-La-Cruz C; Bungau S
    Inflammopharmacology; 2021 Dec; 29(6):1625-1639. PubMed ID: 34669065
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats.
    Ito R; Tsujihata Y; Matsuda-Nagasumi K; Mori I; Negoro N; Takeuchi K
    Br J Pharmacol; 2013 Oct; 170(3):568-80. PubMed ID: 23848179
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ligands at Free Fatty Acid Receptor 1 (GPR40).
    Hara T
    Handb Exp Pharmacol; 2017; 236():1-16. PubMed ID: 27757762
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of highly potent and orally available free fatty acid receptor 1 agonists bearing isoxazole scaffold.
    Li Z; Liu C; Shi W; Cai X; Dai Y; Liao C; Huang W; Qian H
    Bioorg Med Chem; 2018 Feb; 26(3):703-711. PubMed ID: 29291938
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists.
    Negoro N; Sasaki S; Ito M; Kitamura S; Tsujihata Y; Ito R; Suzuki M; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Tanaka T; Yasuma T; Momose Y
    J Med Chem; 2012 Feb; 55(4):1538-52. PubMed ID: 22242551
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery of a potent G-protein-coupled receptor 119 agonist for the treatment of type 2 diabetes.
    Pola S; Shah SR; Pingali H; Zaware P; Thube B; Makadia P; Patel H; Bandyopadhyay D; Rath A; Giri S; Patel JH; Ranvir RK; Sundar SR; Patel H; Kumar J; Jain MR
    Bioorg Med Chem; 2021 Apr; 35():116071. PubMed ID: 33611013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.